Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego Vieyra

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cancer Research|August 3, 2002
ING1 isoforms differentially affect apoptosis in a cell age-dependent mannerDiego Vieyra, Tatsuya Toyama, Yasuo Hara, et al.
Cancer Research|October 3, 2003
ING1 represses transcription by direct DNA binding and through effects on p53Hiromi Kataoka, Paul Bonnefin, Diego Vieyra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Altered subcellular localization and low frequency of mutations of ING1 in human brain tumorsDiego Vieyra, Donna L Senger, Tatsuya Toyama, et al.
The Journal of Biological Chemistry|May 17, 2002
Human ING1 proteins differentially regulate histone acetylationDiego Vieyra, Robbie Loewith, Michelle Scott, et al.
Blood Advances|August 25, 2022
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Blood|December 9, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUSOla Landgren, Ajai Chari, Yael C Cohen, et al.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Research|August 3, 2002
ING1 isoforms differentially affect apoptosis in a cell age-dependent mannerDiego Vieyra, Tatsuya Toyama, Yasuo Hara, et al.
Cancer Research|October 3, 2003
ING1 represses transcription by direct DNA binding and through effects on p53Hiromi Kataoka, Paul Bonnefin, Diego Vieyra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Altered subcellular localization and low frequency of mutations of ING1 in human brain tumorsDiego Vieyra, Donna L Senger, Tatsuya Toyama, et al.
The Journal of Biological Chemistry|May 17, 2002
Human ING1 proteins differentially regulate histone acetylationDiego Vieyra, Robbie Loewith, Michelle Scott, et al.
Blood Advances|August 25, 2022
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Blood|December 9, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUSOla Landgren, Ajai Chari, Yael C Cohen, et al.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 2